Keywords: Prostate, Prostate, Biopsy Indication, PI-RADS, PSAD
Motivation: Prostate cancer diagnosis often relies on biopsies that carry risks, and traditional methods like PSA testing have limited accuracy.
Goal(s): Combine PI-RADS v2.1 scoring with PSAD to reduce unnecessary procedures without missing clinically significant prostate cancer (csPCa).
Approach: A retrospective analysis of 462 patients undergoing prostate biopsies; logistic regression identified independent risk factors; ROC curves evaluated diagnostic performance of the combined PI-RADS v2.1 score and PSAD.
Results: PI-RADS v2.1 score and PSAD are independent risk factors for csPCa. Combining them improved diagnostic accuracy (AUC = 0.964), allowing safe avoidance of biopsies in certain cases.
Impact: By integrating PI-RADS v2.1 scores with PSAD, this study offers a validated method to reduce unnecessary prostate biopsies by 40%, enhancing patient care and diagnostic precision for clinically significant prostate cancer.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords